UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S198-S199

2011

Volltextzugriff (PDF)

Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study

Journal of hepatology, 2017, Vol.66 (1), p.S521-S522

2017

Volltextzugriff (PDF)

The point of care 13C-Methacetin Breath Test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology

Journal of hepatology, 2017, Vol.66 (1), p.S668-S669

2017

Volltextzugriff (PDF)

I-26 Immunology of HBV infection

International journal of infectious diseases, 2008, Vol.12, p.S9-S10

Vierling, J.M

2008

Volltextzugriff (PDF)

481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S197-S197

2011

Volltextzugriff (PDF)

Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE)

Journal of hepatology, 2017, Vol.66 (1), p.S85-S85

2017

Volltextzugriff (PDF)

P0769 : Efficacy of an eight-week regimen of grazoprevir plus elbasvir with and without ribavirin in treatment-naive, noncirrhotic HCV genotype 1B infection

Journal of hepatology, 2015-04, Vol.62, p.S618-S618

2015

Volltextzugriff (PDF)

LO8 : Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study

Journal of hepatology, 2015-04, Vol.62, p.S261-S262

2015

Volltextzugriff (PDF)

Factors Impacting SVR12 for Patients with Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir with Ribavirin in the Ally-1 Study

Journal of hepatology, 2016, Vol.64 (2), p.S768-S769

2016

Volltextzugriff (PDF)

Efficacy and safety of the fixed-dose combination regimen of MK3 [MK-3682/grazoprevir/ruzasvir] with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2)

Journal of hepatology, 2017, Vol.66 (1), p.S315-S316

2017

Volltextzugriff (PDF)

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

Journal of hepatology, 2010, Vol.52, p.S470-S471

2010

Volltextzugriff (PDF)

205 LONG TERM OUTCOMES OF PORTOPULMONARY HYPERTENSION (POPH) AFTER ORTHOTOPIC LIVER TRANSPLANTATION (OLT)

Journal of hepatology, 2013-04, Vol.58, p.S89-S90

2013

Volltextzugriff (PDF)

248 FASTING AMMONIA (NH3) AS A PREDICTOR OF HEPATIC ENCEPHALOPATHY (HE) EVENTS

Journal of hepatology, 2013-04, Vol.58, p.S106-S106

2013

Volltextzugriff (PDF)

O33 SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 mg AND 50 mg DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

Journal of hepatology, 2014-04, Vol.60 (1), p.S14-S14

2014

Volltextzugriff (PDF)

O10 SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172/MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NON-CIRRHOTIC, PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHY STUDY

Journal of hepatology, 2014-04, Vol.60 (1), p.S5-S5

2014

Volltextzugriff (PDF)

LP17 : Novel approach for the prevention of recurrent hepatitis C in liver transplant recipients: Preliminary results from ongoing phase III trial with civacir

Journal of hepatology, 2015-04, Vol.62, p.S271-S272

2015

Volltextzugriff (PDF)

627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES

Journal of hepatology, 2009, Vol.50, p.S230-S231

2009

Volltextzugriff (PDF)

308 VIROLOGIC AND METABOLIC RESPONSES IN CHRONIC HEPATITIS C (CHC) PATIENTS WITH INSULIN RESISTANCE (IR) TREATED WITH PIOGLITAZONE AND PEGINTERFERON ALFA-2A PLUS RIBAVIRIN

Journal of hepatology, 2010, Vol.52, p.S129-S129

2010

Volltextzugriff (PDF)

P1130 FUTILITY TESTING AT TREATMENT WEEK 8 IN PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION RECEIVING BOCEPREVIR: A POST HOC ANALYSIS

Journal of hepatology, 2014-04, Vol.60 (1), p.S457-S458

2014

Volltextzugriff (PDF)

66 HIGH SUSTAINED VIRAL RESPONSE AT 12- AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

Journal of hepatology, 2013-04, Vol.58, p.S30-S30

2013

Volltextzugriff (PDF)

13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION

Journal of hepatology, 2013-04, Vol.58, p.S6-S6

2013

Volltextzugriff (PDF)

1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS

Journal of hepatology, 2013-04, Vol.58, p.S576-S577

2013

Volltextzugriff (PDF)

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES

Journal of hepatology, 2011-03, Vol.54, p.S4-S4

2011

Volltextzugriff (PDF)

452 EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S184-S184

2011

Volltextzugriff (PDF)

449 OVERALL SAFETY PROFILE OF BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S183-S183

2011

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Gastroenterology And Hepatology
(28)
Science & Technology
(9)
Life Sciences & Biomedicine
(7)
Biological And Medical Sciences
(4)
Humans
(3)
Adult
(2)
Animals
(2)
Chemistry
(2)
Fundamental And Applied Biological Sciences. Psychology
(2)
Gene
(2)
Genes
(2)
Genetics & Heredity
(2)
Glycine Max
(2)
Heterodera Glycines
(2)
Liver - Metabolism
(2)
Medical Sciences
(2)
Middle Aged
(2)
Physical Sciences
(2)
Plant Sciences
(2)
Surgery
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study

The point of care 13C-Methacetin Breath Test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology

I-26 Immunology of HBV infection

481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE)

P0769 : Efficacy of an eight-week regimen of grazoprevir plus elbasvir with and without ribavirin in treatment-naive, noncirrhotic HCV genotype 1B infection

LO8 : Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study

Factors Impacting SVR12 for Patients with Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir with Ribavirin in the Ally-1 Study

Efficacy and safety of the fixed-dose combination regimen of MK3 [MK-3682/grazoprevir/ruzasvir] with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2)

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

205 LONG TERM OUTCOMES OF PORTOPULMONARY HYPERTENSION (POPH) AFTER ORTHOTOPIC LIVER TRANSPLANTATION (OLT)

248 FASTING AMMONIA (NH3) AS A PREDICTOR OF HEPATIC ENCEPHALOPATHY (HE) EVENTS

O33 SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 mg AND 50 mg DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

O10 SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172/MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NON-CIRRHOTIC, PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHY STUDY

LP17 : Novel approach for the prevention of recurrent hepatitis C in liver transplant recipients: Preliminary results from ongoing phase III trial with civacir

627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES

308 VIROLOGIC AND METABOLIC RESPONSES IN CHRONIC HEPATITIS C (CHC) PATIENTS WITH INSULIN RESISTANCE (IR) TREATED WITH PIOGLITAZONE AND PEGINTERFERON ALFA-2A PLUS RIBAVIRIN

P1130 FUTILITY TESTING AT TREATMENT WEEK 8 IN PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION RECEIVING BOCEPREVIR: A POST HOC ANALYSIS

66 HIGH SUSTAINED VIRAL RESPONSE AT 12- AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION

1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES

452 EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

449 OVERALL SAFETY PROFILE OF BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Suchergebnisse filtern